Literature DB >> 4008377

In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus.

Y Obana, T Nishino, T Tanino.   

Abstract

The virulence of clinical isolates of Acinetobacter calcoaceticus subsp. anitratus was studied in mice, and in-vitro and in-vivo activities of several antimicrobial agents were evaluated. In in-vitro susceptibility testings, tetracyclines, aminoglycosides, and peptide were highly sensitive, and minocycline and doxycycline were the most active of 21 antibiotics tested against 84 clinical isolates of Acin. calcoaceticus. Virulence tests for mice revealed that some strains exhibited high virulence with LD50 values between 10(3) and 10(4) viable cells/mouse. Against lethal and urinary tract infections produced by Acin. calcoaceticus Ac-54 strain in mice, minocycline, doxycycline, gentamicin, and dibekacin, which were highly active in vitro, were effective.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008377     DOI: 10.1093/jac/15.4.441

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6).

Authors:  W H Traub; M Spohr
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance.

Authors:  Jessica M Breslow; Joseph J Meissler; Rebecca R Hartzell; Phillip B Spence; Allan Truant; John Gaughan; Toby K Eisenstein
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore.

Authors:  B G Kuah; G Kumarasinghe; J Doran; H R Chang
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.

Authors:  Greg Harris; Bruce E Holbein; Hongyan Zhou; H Howard Xu; Wangxue Chen
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

6.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.

Authors:  A Montero; J Ariza; X Corbella; A Doménech; C Cabellos; J Ayats; F Tubau; C Ardanuy; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem.

Authors:  M L Joly-Guillou; M Wolff; J J Pocidalo; F Walker; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

9.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  Detection of Acinetobacter spp. in rural drinking water supplies.

Authors:  J M Bifulco; J J Shirey; G K Bissonnette
Journal:  Appl Environ Microbiol       Date:  1989-09       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.